{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:00Z","timestamp":1793656500312,"version":"4.5.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10147-023-02334-w","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T05:31:57Z","timestamp":1681795917000},"page":"816-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8361-9973","authenticated-orcid":false,"given":"Hideki","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Toratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Shimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Senjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"issue":"1","key":"2334_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD (2015) Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125(1):22\u201332","journal-title":"Blood"},{"issue":"4","key":"2334_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351\u2013363","journal-title":"N Engl J Med"},{"issue":"16","key":"2334_CR3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808","journal-title":"Blood"},{"issue":"1","key":"2334_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2015.213","volume":"51","author":"E Van Den Neste","year":"2016","unstructured":"Van Den Neste E, Schmitz N, Mounier N et al (2016) Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant 51(1):51\u201357","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2334_CR5","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P et al (2021) Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22(10):1403\u20131415","journal-title":"Lancet Oncol"},{"issue":"21","key":"2334_CR6","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu ZH, Curran K et al (2020) Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 4(21):5414\u20135424","journal-title":"Blood Adv"},{"issue":"9","key":"2334_CR7","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1007\/s10147-020-01699-6","volume":"25","author":"H Goto","year":"2020","unstructured":"Goto H, Makita S, Kato K et al (2020) Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed\/refractory diffuse large B-cell lymphoma. Int J Clin Oncol 25(9):1736\u20131743","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"2334_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"22","key":"2334_CR9","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S et al (2020) Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv 4(22):5607\u20135615","journal-title":"Blood Adv"},{"issue":"27","key":"2334_CR10","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"12","key":"2334_CR11","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra AJ et al (2019) Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive b cell non-Hodgkin lymphoma: an expert panel opinion from the american society for transplantation and cellular therapy. Biol Blood Marrow Transplant 25(12):2305\u20132321","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2334_CR12","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/bloodadvances.2020001816","volume":"4","author":"H Senjo","year":"2020","unstructured":"Senjo H, Hirata K, Izumiyama K et al (2020) High metabolic heterogeneity on baseline 18FDG-PET\/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma. Blood Adv 4(10):2286\u20132296","journal-title":"Blood Adv"},{"issue":"8","key":"2334_CR13","doi-asserted-by":"publisher","first-page":"e105682","DOI":"10.1371\/journal.pone.0105682","volume":"9","author":"K Hirata","year":"2014","unstructured":"Hirata K, Kobayashi K, Wong KP et al (2014) A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE 9(8):e105682","journal-title":"PLoS ONE"},{"issue":"3","key":"2334_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"2334_CR15","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA et al (2019) The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133(17):1876\u20131887","journal-title":"Blood"},{"issue":"15","key":"2334_CR16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV et al (2019) Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133(15):1652\u20131663","journal-title":"Blood"},{"issue":"5\u20136","key":"2334_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/10428199509056860","volume":"17","author":"AH Sarris","year":"1995","unstructured":"Sarris AH, Majlis A, Dimopoulos MA et al (1995) Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Leuk Lymphoma 17(5\u20136):473\u2013477","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2334_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s00134-016-4220-z","volume":"42","author":"J Bakker","year":"2016","unstructured":"Bakker J, de Backer D, Hernandez G (2016) Lactate-guided resuscitation saves lives: we are not sure. Intensive Care Med 42(3):472\u2013474","journal-title":"Intensive Care Med"},{"issue":"3","key":"2334_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0025-7125(16)30345-5","volume":"76","author":"IA Tabbara","year":"1992","unstructured":"Tabbara IA (1992) Hemolytic anemias. Diagnosis and management. Med Clin North Am 76(3):649\u2013668","journal-title":"Med Clin North Am"},{"key":"2334_CR20","doi-asserted-by":"publisher","first-page":"713577","DOI":"10.3389\/fonc.2021.713577","volume":"11","author":"R Hong","year":"2021","unstructured":"Hong R, Yin TS, E, Wang L, et al (2021) Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-Cell therapy in non-Hodgkin lymphoma. Front Oncol 11:713577","journal-title":"Front Oncol"},{"issue":"4","key":"2334_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2334_CR22","doi-asserted-by":"publisher","first-page":"e150807","DOI":"10.1172\/JCI150807","volume":"132","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli S, Bove C, Mezzanotte C et al (2022) CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest 132(12):e150807","journal-title":"J Clin Invest"},{"issue":"6","key":"2334_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J et al (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24(6):731\u2013738","journal-title":"Nat Med"},{"issue":"1","key":"2334_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S et al (2021) Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res 40(1):367","journal-title":"J Exp Clin Cancer Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02334-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02334-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02334-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T09:11:11Z","timestamp":1685524271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02334-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2334"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02334-w","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.G. has received honoraria from Bristol-Myers Squibb, Eisai, Janssen, Chugai, Novartis, SymBio, Kyowa-Kirin, Astellas, MSD and Daiichi-Sankyo; and has received research grants from Bristol-Myers Squibb and Kyowa-Kirin; and has received research funding from Kyowa-Kirin, AbbVie and Chugai. T.K. has received honoraria from Novartis, Otsuka, Bristol-Myers Squibb, Chugai, SymBio and Asahi Kasei. N.F. has received honoraria from Novartis, Chugai, Daiichi-Sankyo, Nippon Shinyaku, Janssen, Pfizer and Astellas. K.K. has received honoraria from Novartis, Chugai and Kyowa-Kirin; and has received research funding from Chugai, Takeda, Kyowa-Kirin, AbbVie, Novartis, Eisai, Janssen, Bristol-Myers Squibb, Ono and Daiichi-Sankyo. Y.O. has received honoraria from Novartis, Pfizer, Janssen, AbbVie, Chugai, Bristol-Myers Squibb, Amgen, Kyowa-Kirin, SymBio, Astellas, MSD, Meiji Seika; and has received research funding from Novartis, Pfizer, Janssen and Takara Bio. N.F. has received honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai, CLS Behring, Dainippon Sumitomo, Eisai, Janssen, Kyowa-Kirin, Nippon Shinyaku, Novartis, Ono, Otsuka, Sanofi, SymBio, Takeda and Zenyaku; and has received research funding from Bayer, Chugai, Celgene, Genmab and Incyte. K.O. has received honoraria from Novartis, AbbVie, Astellas, Janssen and Nippon Shinyaku; and has received research funding from Bristol-Myers Squibb, Celgene and Agois. T.Y., K.T., H.K., S.Y., M.S., H.S. M.O. and K.H. declare no competing interests. I.Y. has received grants from KAKENHI, AMED and Health, Labor and Welfare Policy Research Grants; and has received research funding from Nippon Medi-Physis; and has received honoraria from Chugai, Astra Zeneca and Nippon-Shinyaku. T.T. has received honoraria from Merck Sharp and Dohme, Takeda, Kyowa-Kirin, Bristol-Myers Squibb and Pfizer; and has received research funding from Chugai, Kyowa-Kirin, Sanofi, Astellas, TEIJIN PHARMA, Novartis, Fuji Pharma and Nippon Shinyaku; and served on an advisory board for Takeda and Novartis; and has participated in manuscript preparation as other financial interests for Janssen and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}